Reported Earlier, AstraZeneca And Ionis' WAINUA™ Granted Regulatory Approval In The U.S. For The Treatment Of Adults With Polyneuropathy Of Hereditary Transthyretin-Mediated Amyloidosis
Portfolio Pulse from Benzinga Newsdesk
The US FDA has approved AstraZeneca and Ionis Pharmaceuticals' WAINUA™ for treating adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis. The approval is based on positive Phase III NEURO-TTRansform study results, which showed that WAINUA consistently improved neuropathy impairment and quality of life. Additional regulatory reviews are in progress globally.
December 22, 2023 | 6:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's recent FDA approval of WAINUA™ could lead to increased revenue from a new treatment option for polyneuropathy of hereditary transthyretin-mediated amyloidosis.
FDA approvals generally lead to positive market reactions as they enable companies to market their drugs in the US, potentially leading to increased sales and revenue. The approval of WAINUA™ could be significant for AstraZeneca, depending on the prevalence of the condition and the drug's market penetration.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Ionis Pharmaceuticals, having co-developed WAINUA™ with AstraZeneca, stands to benefit from the FDA approval through potential sales and royalties.
Ionis Pharmaceuticals' collaboration with AstraZeneca on WAINUA™ means that FDA approval could result in a new income source from drug sales and royalties. The impact on Ionis' financials will depend on the commercial success of the drug.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80